According to a recent study, the out-of-pocket clinical costs and capitalized clinical costs per approved drug were both lower for orphan drugs compared with nonorphan drugs.
According to a recent study, the out-of-pocket clinical costs and capitalized clinical costs per approved drug were both lower for orphan drugs compared with nonorphan drugs.
Prior to the Orphan Drug Act, there have been few incentives for pharmaceutical companies to develop drugs for rare diseases. For many of these drugs, the amount spent may not be compensated, leading to minimal profits. Because of these risks, orphan drug prices are substantially higher than regular drug prices. As a result, patients with rare diseases such as cystic fibrosis and Gaucher disease may pay upward of $400,000 per year for their respective treatments.
For pharmaceutical companies to maintain interest in developing orphan drugs, they must be able to recoup costs, but there must also be evidence for the high costs they expect in return. In a recent study, investigators estimated and compared the research and development costs between orphan and nonorphan drugs.
The study comprised a data set of 1163 trials, 561 nonorphan drugs, and 602 orphan drugs. The estimated total out-of-pocket costs for all 3 phases were considerably higher in the orphan group versus the nonorphan group ($55 million vs $30 million). However, after accounting for the overall probability of clinical success, the out-of-pocket clinical costs were $166 million for the orphan group and $291 million for the nonorphan group.
Similarly, for capitalized expected costs, the orphan group had a higher cost compared with the nonorphan group ($96 million vs $43 million). After considering the overall probability of clinical success, the capitalized cost per approved drug was $291 million for the orphan drug group and $412 million for the nonorphan group. Capitalized costs per approved nonorphan drug that is a new molecular entity (NME) were $489 million, whereas the costs per approved orphan drug that is an NME were $242 million.
Based on this study, investigators concluded that the overall cost of orphan drug development is less than that of nonorphan drug development. Because of the variability in trial design, subjects, and length of study, there may have been differences that were not accounted for. Furthermore, the cost of the drug also needs to be valued depending on its place in therapy. Investigators further concluded that more research is needed before setting prices for orphan drugs.
Reference
Jayasundara K, Hollis A, Krahn M, Mamdani M, Hoch JS, Grootendorst P. Estimating the clinical cost of drug development for orphan versus non-orphan drugs. Orphanet J Rare Dis. 2019;14(1):12. doi: 10.1186/s13023-018-0990-4.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More